ARTL

Artelo Biosciences Inc

Add to Watchlist

Advanced Chart

4.660

+0.3(6.881%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.730

Open

4.380

VWAP

4.67

Vol

35.43K

Mkt Cap

9.30M

Low

4.380

Amount

165.36K

EV/EBITDA(TTM)

Total Shares

3.23M

7.43M

EV/OCF(TTM)

P/S(TTM)

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-0.260

-93.98%

-0.140

-98.01%

-0.820

-60.95%

Estimates Revision

The market is revising No Change the revenue expectations for Artelo Biosciences, Inc. (ARTL) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -70.69%.

EPS Estimates for FY2025

Revise Downward

-24.85%

In Past 3 Month

Stock Price

Go Down

-70.69%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast ARTL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARTL is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 4.660

Low

20.00

Averages

20.00

High

20.00

Current: 4.660

Low

20.00

Averages

20.00

High

20.00

D. Boral Capital

Jason Kolbert

Buy

Hold

downgrade

2025-09-08

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-09-08

downgrade

Buy

Hold

Reason

D. Boral Capital analyst Jason Kolbert downgraded Artelo Biosciences to Hold from Buy and removed the firm's prior price target following the company's "unexpected" $3M capital raise last week that came after what appeared to be an unsuccessful crypto-related strategy. Repeated attempts to reach management for clarification have been unsuccessful, notes the analyst, who cites the combination of "poor communication, a confusing strategic direction, and a dilutive capital raise" for the firm's more cautious stance.

D. Boral Capital

Hold

Buy

upgrade

$20

2025-07-08

Reason

D. Boral Capital

Price Target

$20

2025-07-08

upgrade

Hold

Buy

Reason

D. Boral Capital upgraded Artelo Biosciences (ARTL) to Buy from Hold with a $20 price target. The firm, which has adjusted its model and raised assumptions for the now completed reverse split, continues to view Artelo as an emerging biotechnology company focused on Cachexia and Chemotherapy-induced peripheral neuropathy with the lead program ART27.13, a Phase 2 asset acquired from Astra-Zenca (AZN), the analyst tells investors.

D. Boral Capital

Jason Kolbert

Buy

Hold

downgrade

2025-06-11

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-06-11

downgrade

Buy

Hold

Reason

D. Boral Capital analyst Jason Kolbert downgraded Artelo Biosciences to Hold from Buy without a price target after the company announced a 6-for-1 reverse stock split set to take effect on June 13. The firm moved to the sidelines "as the company transitions through this corporate action." The analyst sees limited near-term upside until the shares "find technical and investor support at a new base level."

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-04-02

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-04-02

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

2025-03-04

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

2025-03-04

Reiterates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-03-03

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-03-03

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Artelo Biosciences Inc (ARTL.O) is -1.09, compared to its 5-year average forward P/E of -4.42. For a more detailed relative valuation and DCF analysis to assess Artelo Biosciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.42

Current PE

-1.09

Overvalued PE

6.25

Undervalued PE

-15.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.28

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.33

Undervalued EV/EBITDA

-0.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00